Clinical trial
PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors
NCT00017199 · Ohio State University Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00017199 |
|---|---|
| Title | PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors |
| Official title | Phase II Study of PS-341 in Metastatic Neuroendocrine Tumors |
| Lead sponsor | Ohio State University Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastrointestinal Carcinoid Tumor, Islet Cell Tumor |
| Intervention type | Drug |
| Interventions | bortezomib |
| Start date | Apr 1, 2001 |
| Completion | May 1, 2007 |
| First posted | Feb 16, 2004 |
| Last update posted | Jan 31, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: